- Home
- SBET vs LTGO Comparison
SBET vs LTGO Comparison
Compare SBET & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SBET | LTGO |
|---|---|---|
| Founded | 1995 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2025 | 2026 |
Fundamental Metrics
Financial Performance| Metric | SBET | LTGO |
|---|---|---|
| Price | $8.45 | $15.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | $16.63 | ★ $52.25 |
| AVG Volume (30 Days) | ★ 6.7M | 349.4K |
| Earning Date | 11-11-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $28,055,000.00 | N/A |
| Revenue This Year | $67.70 | N/A |
| Revenue Next Year | $57.94 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 666.04 | N/A |
| 52 Week Low | $4.46 | $14.60 |
| 52 Week High | $16.20 | $25.93 |
Technical Indicators
Market Signals| Indicator | SBET | LTGO |
|---|---|---|
| Relative Strength Index (RSI) | 44.01 | 38.05 |
| Support Level | $7.85 | N/A |
| Resistance Level | $9.27 | $20.49 |
| Average True Range (ATR) | 0.40 | 1.32 |
| MACD | -0.20 | -0.24 |
| Stochastic Oscillator | 4.47 | 23.42 |
Price Performance
Historical ComparisonAbout SBET SharpLink Gaming Ltd.
Sharplink Inc is one of those publicly traded companies to adopt ETH as its primary treasury reserve asset. This move reflects the Company's commitment to align corporate treasury with the future of programmable finance, digital capital markets, and decentralized infrastructure. The Company also operates an online affiliate marketing company that delivers different fan activation solutions to its sportsbook and online casino gaming partners. The company operates in two reportable segments: ETH Treasury Management and Affiliate Marketing. The majority of its revenue is generated from the ETH Treasury Management. Geographically, the company operates in the United States and the rest of the world.
About LTGO Latigo Biotherapeutics Inc. Common Stock
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.